Back

Edoxaban Treatment in routiNe clinical prActice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe): 1-year follow-up according to body mass index

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 3 Stroke in Atrial Fibrillation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Thomas Weiss

University Hospital St. Polten, St. Polten (Austria)

7 More presentations in this session

Presentation thumbnail
Men who live alone have poor anticoagulation control: results from Danish registries.
Doctor A. Nissen Bonde (Roskilde, DK)
Abstract Slides
Presentation thumbnail
VTE-BLEED score predicts major bleeding in patients with atrial fibrillation
Professor E. Klok (Leiden, NL)
Abstract
Presentation thumbnail
Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study
Doctor X. Li (Princeton, US)
Abstract Slides
Presentation thumbnail
Optimal rivaroxaban dose in asian patients with atrial fibrillation and normal or mildly impaired renal function
Doctor E. Choi (Seoul, KR)
Abstract
Presentation thumbnail
Antithrombotic challenge in the clinical dilemma of high-risk patients with atrial fibrillation: one-year result from ChiOTEAF Registry
Professor Y. Guo (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 3

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources